

Giovanni Franchin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8132905/publications.pdf>

Version: 2024-02-01

107
papers

3,084
citations

172207

29
h-index

174990

52
g-index

107
all docs

107
docs citations

107
times ranked

3769
citing authors

#	ARTICLE	IF	CITATIONS
1	Knee Arthrocentesis in Adults. <i>Journal of Visualized Experiments</i> , 2022, , .	0.2	1
2	Radiation recall dermatitis induced by COVID-19 vaccination in breast cancer patients treated with postoperative radiation therapy. <i>Breast</i> , 2022, 65, 49-54.	0.9	7
3	Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1368-1376.	0.4	13
4	Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. <i>Nutrients</i> , 2021, 13, 1277.	1.7	23
5	miRâ€9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. <i>EMBO Molecular Medicine</i> , 2021, 13, e12872.	3.3	15
6	Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders. <i>Medical Science Monitor</i> , 2021, 28, e934267.	0.5	1
7	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 378-384.	0.6	3
8	Direct health-care cost of head and neck cancers: a population-based study in north-eastern Italy. <i>Medical Oncology</i> , 2019, 36, 31.	1.2	11
9	Metabolic disorders and the risk of nasopharyngeal carcinoma: a caseâ€control study in Italy. <i>European Journal of Cancer Prevention</i> , 2018, 27, 180-183.	0.6	11
10	An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3769-3780.	3.2	36
11	The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy. <i>Oral Oncology</i> , 2017, 67, 175-182.	0.8	50
12	Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and head and neck cancers risk. <i>Oral Oncology</i> , 2017, 64, 59-64.	0.8	17
13	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2017, 9, 58.	1.8	32
14	Lowâ€dose radiotherapy in diffuse large Bâ€cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 472-479.	0.8	9
15	Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature. <i>Hormones</i> , 2017, 13, 322-327.	0.9	9
16	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 431-440.	1.6	19
17	Post-chikungunya rheumatic disorders in travelers after return from the Caribbean. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 21-25.	1.5	20
18	Combined effect of tobacco smoking and alcohol drinking in the risk of head and neck cancers: a re-analysis of caseâ€control studies using bi-dimensional spline models. <i>European Journal of Epidemiology</i> , 2016, 31, 385-393.	2.5	60

#	ARTICLE	IF	CITATIONS
19	Etanercept-induced myositis: do we have to stop it? A surprising outcome. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213577.	0.2	4
20	Effectiveness of selective neck dissection in head and neck cancer: The experience of two Italian centers. <i>Laryngoscope</i> , 2015, 125, 1849-1855.	1.1	9
21	Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 606-613.	0.4	42
22	Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy. <i>Biomarkers</i> , 2015, 20, 422-428.	0.9	17
23	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. <i>Journal of Radiotherapy</i> , 2014, 2014, 1-7.	0.2	1
24	IMRT with concomitant boost versus conventional radiation in the setting of sequential chemoradiotherapy for oropharyngeal cancer. <i>Journal of Radiotherapy in Practice</i> , 2014, 13, 418-427.	0.2	0
25	Collapsing Focal Segmental Glomerulosclerosis in a Patient with Systemic Lupus Erythematosus. <i>Case Reports in Medicine</i> , 2014, 2014, 1-5.	0.3	7
26	Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1114-1119.	0.4	79
27	Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. <i>Lung Cancer</i> , 2014, 83, 78-82.	0.9	76
28	Anti-DNA antibodies cross-react with C1q. <i>Journal of Autoimmunity</i> , 2013, 44, 34-39.	3.0	27
29	Fiber Intake and Risk of Nasopharyngeal Carcinoma: A Case-Control Study. <i>Nutrition and Cancer</i> , 2013, 65, 1157-1163.	0.9	13
30	Dose to the skin in helical tomotherapy: Results of in vivo measurements with radiochromic films. <i>Physica Medica</i> , 2013, 29, 304-311.	0.4	26
31	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. <i>BMC Cancer</i> , 2013, 13, 513.	1.1	16
32	The Structure and Derivation of Antibodies and Autoantibodies. , 2013, , 76-95.		3
33	Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1862-1866.	0.5	53
34	Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. <i>Journal of Cellular Physiology</i> , 2012, 227, 233-238.	2.0	9
35	Treatment of recurrent high-grade gliomas with GliSite brachytherapy: A prospective mono-institutional Italian experience. <i>Tumori</i> , 2011, 97, 614-619.	0.6	13
36	Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. <i>Oral Oncology</i> , 2011, 47, 541-545.	0.8	70

#	ARTICLE	IF	CITATIONS
37	Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. <i>Oral Oncology</i> , 2011, 47, 905-909.	0.8	6
38	Helical Tomotherapy in Children and Adolescents: Dosimetric Comparisons, Opportunities and Issues. <i>Cancers</i> , 2011, 3, 3972-3990.	1.7	10
39	Treatment of recurrent high-grade gliomas with GliSite brachytherapy: a prospective mono-institutional Italian experience. <i>Tumori</i> , 2011, 97, 614-9.	0.6	9
40	Optimizing Craniospinal Radiotherapy Delivery in a Pediatric Patient Affected by Supratentorial PNET: A Case Report. <i>Tumori</i> , 2010, 96, 316-321.	0.6	5
41	Correlation of a hypoxia based tumor control model with observed local control rates in nasopharyngeal carcinoma treated with chemoradiotherapy. <i>Medical Physics</i> , 2010, 37, 1533-1544.	1.6	12
42	Optimizing craniospinal radiotherapy delivery in a pediatric patient affected by supratentorial PNET: a case report. <i>Tumori</i> , 2010, 96, 316-21.	0.6	2
43	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. <i>International Journal of Cancer</i> , 2009, 125, 1358-1364.	2.3	18
44	Postoperative reduced dose of cisplatin concomitant with radiation therapy in high-risk head and neck squamous cell carcinoma. <i>Cancer</i> , 2009, 115, 2464-2471.	2.0	13
45	Rheumatology fellows' perception on training and careers in academia: The American College of Rheumatology Fellow Research and Academic Training Survey. <i>Arthritis and Rheumatism</i> , 2009, 61, 266-273.	6.7	8
46	Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 719-726.	0.8	10
47	Spontaneous T cell responses to Epstein-Barr virus-encoded BART1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. <i>International Journal of Cancer</i> , 2008, 123, 1100-1107.	2.3	32
48	Detection and Restaging of Residual and/or Recurrent Nasopharyngeal Carcinoma after Chemotherapy and Radiation Therapy: Comparison of MR Imaging and FDG PET/CT. <i>Radiology</i> , 2008, 249, 203-211.	3.6	111
49	A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. <i>Anti-Cancer Drugs</i> , 2008, 19, 739-744.	0.7	23
50	WE-C-AUD B-01: Tumor Control Probability of Undifferentiated Nasopharyngeal Cancer. <i>Medical Physics</i> , 2008, 35, 2933-2933.	1.6	0
51	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. <i>Infectious Agents and Cancer</i> , 2007, 2, 5.	1.2	21
52	Long-Term Results of Conventional Radiotherapy versus Accelerated Hyperfractionated Radiotherapy versus Concomitant Radiotherapy and Chemotherapy in Locoregionally Advanced Carcinoma of the Oropharynx. <i>Tumori</i> , 2006, 92, 41-54.	0.6	35
53	Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 23-30.	2.0	63
54	Pulse steroids: How much is enough?. <i>Autoimmunity Reviews</i> , 2006, 5, 111-113.	2.5	47

#	ARTICLE	IF	CITATIONS
55	Treatment of head and neck cancer in elderly patients: state of the art and guidelines. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 71-80.	2.0	73
56	Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. <i>Oral Oncology</i> , 2005, 41, 526-533.	0.8	10
57	Role of Rho family GTPases in CCR1- and CCR5-induced actin reorganization in macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 909-916.	1.0	33
58	Pathogenesis of SLE: implications for rational therapy. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 303-308.	0.8	2
59	Radiotherapy for patients with early-stage glottic carcinoma. <i>Cancer</i> , 2003, 98, 765-772.	2.0	80
60	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 78-92.	0.4	112
61	Î²-Chemokine production in CD40L-stimulated monocyte-derived macrophages requires activation of MAPK signaling pathways. <i>Cytokine</i> , 2003, 23, 53-63.	1.4	8
62	Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. <i>Journal of Leukocyte Biology</i> , 2003, 74, 781-790.	1.5	10
63	Dual effects of macrophage inflammatory protein-1Î± on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. <i>Blood</i> , 2003, 102, 311-319.	0.6	199
64	Active Site Residues of Cyclophilin A Are Crucial for Its Signaling Activity via CD147. <i>Journal of Biological Chemistry</i> , 2002, 277, 22959-22965.	1.6	283
65	Squamous cell carcinoma of the hypopharynx treated with surgery and radiotherapy. <i>Journal of Laryngology and Otology</i> , 2002, 116, 24-8.	0.4	15
66	Nasopharyngeal cancer WHO type II-III: monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy. <i>Oral Oncology</i> , 2002, 38, 137-144.	0.8	11
67	Changes in presentation and survival of head and neck carcinomas in Northeastern Italy, 1975-1998. <i>Cancer</i> , 2002, 95, 540-552.	2.0	13
68	The EORTC quality of life questionnaire-head and neck 35 in Italian laryngectomized patients. <i>European organization for research and treatment of cancer. Quality of Life Research</i> , 2000, 9, 1147-1153.	1.5	25
69	Lipopolysaccharide Inhibits HIV-1 Infection of Monocyte-Derived Macrophages Through Direct and Sustained Down-Regulation of CC Chemokine Receptor 5. <i>Journal of Immunology</i> , 2000, 164, 2592-2601.	0.4	66
70	The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. <i>Oral Oncology</i> , 1999, 35, 203-208.	0.8	30
71	Radiation treatment of glottic squamous cell carcinoma, stage I and II: Analysis of factors affecting prognosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 541-548.	0.4	37
72	Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms. <i>Oral Oncology</i> , 1998, 34, 119-122.	0.8	25

#	ARTICLE	IF	CITATIONS
73	Immunization with a plasmid DNA containing the gene of trans-sialidase reduces <i>Trypanosoma cruzi</i> infection in mice. <i>Vaccine</i> , 1998, 16, 768-774.	1.7	104
74	Kaposi's Sarcoma in a Heart Transplant Patient. <i>Acta Oncol</i> ³gica, 1998, 37, 769-770.	0.8	2
75	Combined Modality Treatment of Locally Advanced Lung Cancer. <i>Tumori</i> , 1998, 84, 259-269.	0.6	3
76	Variations in Tumor Levels of Cis-Platinum through a Course of Fractionated Radiotherapy in Patients with Non-Small Cell Lung Cancer. <i>Tumori</i> , 1997, 83, 904-906.	0.6	0
77	A follow-up study of determinants of second tumor and metastasis among subjects with cancer of the oral cavity, pharynx, and larynx. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 367-372.	2.4	35
78	Squamous cell carcinoma of the posterior pharyngeal wall: characteristics compared with the lateral wall. <i>Journal of Laryngology and Otology</i> , 1995, 109, 120-125.	0.4	13
79	Brief report: Prognostic importance of cellular DNA content in T1-2 N0 laryngeal squamous cell carcinomas treated with radiotherapy. <i>Laryngoscope</i> , 1995, 105, 649-652.	1.1	20
80	Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study. <i>Cancer</i> , 1995, 75, 1025-1029.	2.0	10
81	Endometrial Stage I Carcinoma Treated with Surgery and Adjuvant Irradiation: A Retrospective Analysis. <i>Tumori</i> , 1995, 81, 256-260.	0.6	7
82	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. <i>Cancer</i> , 1994, 74, 978-984.	2.0	20
83	Results of Three Consecutive Combined Treatments for Malignant Gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 437-443.	0.6	8
84	The efficacy of radiotherapy in the treatment of intraocular metastases. <i>British Journal of Radiology</i> , 1993, 66, 699-702.	1.0	31
85	Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. <i>Radiotherapy and Oncology</i> , 1992, 23, 241-244.	0.3	17
86	Hyperthermia in Clinical Practice: Preliminary Results and Current Problems in the Treatment of 21 Patients. <i>Tumori</i> , 1992, 78, 262-265.	0.6	1
87	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 11-15.	0.4	174
88	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 573-574.	0.4	10
89	Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1991, 41, 206-211.	0.6	7
90	Evaluation of hospital care in a radiotherapy department in North-eastern Italy. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1253-1258.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma. <i>Tumori</i> , 1991, 77, 61-64.	0.6	18
92	Feasibility of Total Body Irradiation in Chronic Lymphocytic Leukemia and Low-Grade Non-Hodgkin's Lymphomas. <i>Cancer Investigation</i> , 1991, 9, 403-407.	0.6	9
93	Carcinoma of the nasal vestibule: Report of 12 cases. <i>Journal of Laryngology and Otology</i> , 1990, 104, 9-11.	0.4	11
94	Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma a randomized study. <i>Cancer</i> , 1990, 65, 400-404.	2.0	90
95	Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer. <i>Tumori</i> , 1989, 75, 47-52.	0.6	7
96	Multiple fraction per day radiation therapy for inoperable esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 14, 855-860.	0.4	17
97	Accelerated split course regimen in the treatment of brain metastases. <i>Radiotherapy and Oncology</i> , 1988, 12, 39-44.	0.3	12
98	Ovarian Cancer: Ten-Year Experience in a Community Hospital. <i>Tumori</i> , 1987, 73, 381-388.	0.6	0
99	Intermittent pelvic arterial infusion with peptichemio, doxorubicin, and cisplatin for locally advanced and recurrent carcinoma of the uterine cervix. <i>Cancer</i> , 1987, 60, 25-30.	2.0	36
100	Splenic irradiation in chronic lymphocytic leukemia. A 10-year experience at a single institution. <i>Cancer</i> , 1987, 60, 2624-2628.	2.0	19
101	Etoposide (VP-16-213) in malignant brain tumors: a phase II study.. <i>Journal of Clinical Oncology</i> , 1984, 2, 432-437.	0.8	94
102	A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients. <i>Cancer</i> , 1984, 54, 393-396.	2.0	20
103	Phase II study of VM 26 in extensively pretreated breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 451-452.	0.6	3
104	Treatment of grade III and IV astrocytoma with high-dose irradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 265-268.	0.6	2
105	Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1982, 8, 1051-1054.	0.4	8
106	VM26 in malignant hematological diseases. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 7, 173-4.	1.1	6
107	Adriamycin, Bleomycin, Vinblastine and DTIC in Advanced Diffuse Lymphocytic Poorly Differentiated Lymphoma. <i>Tumori</i> , 1981, 67, 477-481.	0.6	1